Decimmune Therapeutics' Grant

Decimmune Therapeutics raised a round of funding on September 28, 2010. Investors include National Institutes of Health.

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's a…

Articles about Decimmune Therapeutics' Grant: